Molloy E S, Morgan M P, Doherty G A, McDonnell B, Hilliard M, O'Byrne J, Fitzgerald D J, McCarthy G M
Department of Molecular and Cellular Therapeutics, Royal College of Surgeons of Ireland.
Rheumatology (Oxford). 2008 Jul;47(7):965-71. doi: 10.1093/rheumatology/ken144. Epub 2008 Apr 30.
Basic calcium phosphate (BCP) crystals have been implicated in the pathogenesis of OA and stimulate cyclo-oxygenase (COX) expression and PGE(2) production. This study aimed to elucidate the mechanism of COX-1 up-regulation by BCP crystals and to characterize the PGs produced in OA synovial fibroblasts (OASFs) in response to BCP crystals.
OASFs were stimulated with BCP crystals in vitro. mRNA expression was measured by real-time PCR, PG production by EIA and protein production by western blot.
Maximal (19-fold) up-regulation of COX-1 mRNA occurred 32 h after stimulation with BCP crystals; increased COX-1 protein production was also seen. At 32 h post-stimulation with BCP crystals, PGE(2) (and prostacyclin) production was COX-1 dependent. In contrast, maximal (17-fold) up-regulation of COX-2, with corresponding COX-2-dependent PG production, occurred 4 h after BCP crystal stimulation. There was no appreciable increased production of other PGs such as PGF(2alpha), thromboxane A(2) or cyclopentanone PGs including 15d-PGJ(2). Inhibition of protein kinase C (PKC) and extracellular regulated kinase 1/2 (ERK1/2) signal transduction pathways blocked BCP crystal-induced COX-1 mRNA expression. Bafilomycin A1, an inhibitor of intra-lysosomal BCP crystal dissolution, diminished BCP crystal-induced COX-1 mRNA expression.
These findings indicate that BCP crystals can augment PG production in OASF through induction of COX-1 and COX-2. Intra-lysosomal BCP crystal dissolution and activity of the PKC and ERK1/2 signal transduction pathways are required for BCP crystal-induced COX-1 up-regulation. These data add to the evidence suggesting that the constitutive COX-1/inducible COX-2 concept is an over-simplification and suggest that non-selective COX inhibition may be preferable to COX-2 selective inhibition in BCP crystal-associated OA.
碱性磷酸钙(BCP)晶体与骨关节炎(OA)的发病机制有关,并能刺激环氧化酶(COX)表达和前列腺素E2(PGE2)生成。本研究旨在阐明BCP晶体上调COX-1的机制,并鉴定OA滑膜成纤维细胞(OASFs)中响应BCP晶体而产生的前列腺素(PGs)。
体外用BCP晶体刺激OASFs。通过实时聚合酶链反应(PCR)测量mRNA表达,通过酶免疫分析(EIA)测量PG生成,通过蛋白质印迹法测量蛋白质生成。
用BCP晶体刺激32小时后,COX-1 mRNA出现最大上调(19倍);同时也观察到COX-1蛋白生成增加。在用BCP晶体刺激后32小时,PGE2(和前列环素)生成依赖于COX-1。相比之下,COX-2最大上调(17倍)以及相应的依赖于COX-2的PG生成在BCP晶体刺激后4小时出现。其他PGs如前列腺素F2α(PGF2α)、血栓素A2(TXA2)或环戊酮PGs(包括15d-前列腺素J2(15d-PGJ2))的生成没有明显增加。蛋白激酶C(PKC)和细胞外调节激酶1/2(ERK1/2)信号转导途径的抑制阻断了BCP晶体诱导的COX-1 mRNA表达。巴弗洛霉素A1(一种溶酶体内BCP晶体溶解的抑制剂)减少了BCP晶体诱导的COX-1 mRNA表达。
这些发现表明,BCP晶体可通过诱导COX-1和COX-2增加OASF中的PG生成。溶酶体内BCP晶体溶解以及PKC和ERK1/2信号转导途径的活性是BCP晶体诱导COX-1上调所必需的。这些数据进一步证明,组成型COX-1/诱导型COX-2的概念过于简单化,并表明在与BCP晶体相关的OA中,非选择性COX抑制可能比COX-2选择性抑制更可取。